MBX Biosciences (MBX) Accumulated Expenses (2023 - 2026)

MBX Biosciences has disclosed Accumulated Expenses across 4 years of filings, most recently posting $7.4 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $7.4 million, up 504.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.4 million (up 504.32% YoY), and the FY2025 annual result was $12.3 million, up 431.24% from the prior year.
• Accumulated Expenses came in at $7.4 million for Q1 2026 at MBX Biosciences, down from $12.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $12.3 million in Q4 2025 to a low of $1.2 million in Q1 2025.
• The 4-year median for Accumulated Expenses is $4.3 million (2024), against an average of $4.9 million.
• Across the five-year window, Accumulated Expenses sank 51.7% in 2025 and soared 504.32% in 2026, its largest moves.
• MBX Biosciences' Accumulated Expenses stood at $1.4 million in 2023, then soared by 70.26% to $2.3 million in 2024, then surged by 431.24% to $12.3 million in 2025, then tumbled by 39.94% to $7.4 million in 2026.
• The last three Accumulated Expenses figures came in at $7.4 million (Q1 2026), $12.3 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.